NeuroOne Appoints Veteran Med-Tech Analyst Jason Mills to Board of Directors

NeuroOne Medical Technologies Corporation announced the appointment of Jason Mills to its Board of Directors, effective December 18, 2025. Mills currently serves as Executive Vice President of Strategy at Penumbra, Inc., where he leads long-range planning, financial planning and analysis, business development, and investor relations for the world's leading thrombectomy company. His appointment represents a strategic addition to NeuroOne's leadership as the company advances its mission to transform surgical diagnosis and treatment of neurological disorders.

Mills brings more than two decades of medical technology industry experience to NeuroOne's board, including over thirteen years as Managing Director and head of the medical technology equity research practice at Canaccord Genuity. During his tenure as a dedicated med-tech investment analyst, he prepared financial models and forecasts, published research, and conducted due diligence on dozens of public and private companies in the sector. His analytical work earned him recognition as the #2 ranked Medical Devices analyst in The Wall Street Journal's 2011 'Best on the Street' Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts.

Dave Rosa, CEO of NeuroOne, emphasized the significance of Mills' appointment, stating, "We are privileged to welcome Jason to NeuroOne with his strong background in med-tech in both corporate settings and as an industry investment analyst. Having known Jason since he was at Canaccord, I know he brings unparalleled and invaluable experience and insights in med-tech. His firsthand knowledge of our industry, combined with his investment and capital markets expertise, will be a critical resource as we progress on our clinical and corporate goals." This endorsement highlights how Mills' dual perspective from both corporate strategy and investment analysis positions him to contribute meaningfully to NeuroOne's strategic direction.

Paul Buckman, Chairman of the Board of Directors, added that Mills will serve on the Compensation and Nominating & Corporate Governance Committees while helping the company expand its reach in transforming neurological disorder diagnosis and treatment. Mills' educational background includes a BA in Economics from Yale University and a Masters in Sports Administration from Ohio University, providing him with a diverse foundation for his corporate and analytical roles. NeuroOne is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.

The appointment matters because it strengthens NeuroOne's governance with specialized industry expertise at a critical juncture in the company's development. Mills' experience at Penumbra, a publicly-traded medical technology leader, combined with his extensive background analyzing medical device companies, provides NeuroOne with strategic insights that could enhance its clinical development, corporate positioning, and shareholder value creation. His understanding of capital markets and investor relations is particularly valuable for a Nasdaq-listed company like NeuroOne as it navigates the competitive landscape of neurological treatment technologies. The implications extend to potentially improved strategic decision-making, enhanced industry relationships, and more effective communication with the investment community as NeuroOne advances its portfolio of neurological disorder solutions.